


Patent claims.

1. A compound according to formula I



wherein R1 = -H, -CN, -COO+, -COS+, -COOH, -COSH, -COOR1.1, -COSR1.1, N-phthalimidyl,

wherein R1.1 = -H, C1-10 alkyl, C1-10 aralkyl or aryl,

wherein R2 = -H, C1-C4 alkyl, -OR1.1, -Hal (-F -Cl, -Br, -J), -NR2.1R2.2, -Am, -O-Am, -S-Am,

wherein R3 = -H, C1-C4 alkyl, -OR1.1, -Hal (-F -Cl, -Br, -J), -NR2.1R2.2, -Am, -O-Am, -S-Am,

wherein R2.1 = -H, C1-10 alkyl, C1-10 aralkyl or aryl,

wherein R2.2 = -H, C1-10 alkyl, C1-10 aralkyl or aryl,

wherein R2.1 and R2.2 may be identical or different,

wherein n and m may be identical or different and 0 to 10,

wherein o and p may be identical or different and 0 to 3,

wherein o > 0, if n and m = 0,

wherein R2 and R3 may be identical or different for Cn and/or Cm,

wherein R2 may be identical or different for every Cx = 1 ... n,

wherein R3 may be identical or different for every Cy = 1 ... m,

wherein -Am is an amino acid radical,

wherein q and r = 0 or 1 and identical or
5 different,

wherein -O_r- and/or -O_q- may also be replaced by -S_r- or -S_q-, resp.,

wherein -NR2.1R2.2 may be replaced by a linear or branched -C1-C20 alkyl, aralkyl or aryl,

10 wherein a group -CN, -(CO)-CN, -(CO)-O-R1 or -(CO)-R1 or -C-O-R1 may be replaced by -SO₂-NR2.1R2.2,

or a physiologically well tolerated salt of such a compound.

15

2. A compound according to claim 1, wherein R1 = -CN.

20 3. A compound according to claim 1 or 2, wherein R2 exists at least singly as -Am, wherein -Am preferably represents an amino acid radical of an essential amino acid, wherein in particular q = 0 and r = 1 or q = 1 and r = 0 or q = 1 and r = 1, m = 1, R3 = -H, n = o = p = 0,
25 R2.1 = R2.2 = -H.

4. A compound according to claim 1 or 2, wherein n = o = p = 0, wherein m = 0 to 4, wherein R2 = R3 = -H, wherein R2.1 = R2.2 = -H,
30 wherein q = 0 and r = 1.

5. A compound according to claim 1 or 2,
wherein $m = p = 0$, wherein $o = 1$, wherein $n = 0$
to 4, wherein $R2 = H$, wherein $R3 = -H$ or $-Hal$ in
the case $Cx = 1$, wherein $R3 = -H$ for all $Cx = n$
5 > 1, wherein $R2.1 = R2.2 = -H$, wherein $q = 0$ and
 $r = 1$.

6. A compound according to claim 1 or 2,
wherein $m = 1$ to 4, wherein $n = o = p = 0$,
10 wherein $R2 = H$, wherein $R3 = -H$ or $-Hal$ in the
case $Cy = 1$, wherein $R3 = -H$ for all $Cy = m > 1$,
wherein $R2.1 = R2.2 = -H$, wherein $q = 0$ and $r =$
1.

15 7. A compound according to claim 1 or 2,
wherein $o = p = 1$, wherein $m = 0$, wherein $n = 0$
to 4, wherein $R2 = R3 = -H$, wherein $R2.1 = R2.2$
 $= -H$, wherein $q = 0$ and $r = 1$.

20 8. A compound according to claim 1 or 2,
wherein $n = p = 0$, wherein $o = 1$, wherein $m = 0$
to 4, wherein $R2 = R3 = -H$, wherein $R2.1 = R2.2$
 $= -H$, wherein $q = 0$ and $r = 1$.

25 9. A compound according to claim 1 or 2,
wherein $m = p = 0$, wherein $o = 1$, wherein $n = 1$
to 4, wherein $R2 = R3 = -H$, wherein $R2.1 = R2.2$
 $= -H$, wherein $q = 0$ and $r = 1$.

10. A compound according to one of claims 4 to 9, wherein one R2 is replaced by -Am.

5 11. The use of a compound according to one of claims 1 to 10 for preparing a pharmaceutical composition for treating one or several diseases of the group comprising "cancer, chronic inflammations, asthma, arthritis, osteoarthritis, chronic polyarthritis, rheumatic arthritis, inflammatory bowl disease, degenerative joint diseases, rheumatic diseases with cartilage disorders, sepsis, autoimmune diseases, type I diabetes, Hashimoto thyroiditis, autoimmune thrombocytopenia, multiple sclerosis, myasthenia gravis, 10 chronically inflammatory intestinal diseases, Crohn's disease, uveitis, psoriasis, collagenoses, Goodpasture syndrome, diseases with disturbed leukocyte adhesion, cachexia, diseases by increased TNF-alpha concentration, diabetes, 15 adiposity, bacterial infections, in particular with resistant bacteria (antibiotic)". 20

25 12. A pharmaceutical composition, wherein a compound according to one of claims 1 to 10 is mixed with one or several physiologically well tolerated auxiliary substances and/or carrier substances and galenically prepared for the local, in particular oral, or systemic, in particular IV, administration.

30

13. The use of a compound according to one of claims 1 to 10 for inhibiting in vitro and/or in

vivo the glycolysis and/or the glutaminolysis,
in particular of pyruvate kinase, asparaginase,
serine dehydratases, transaminases, glutamate
oxalacetate transaminase, glutamate pyruvate
5 transaminase, glutamate dehydrogenase, malate
dehydrogenase, desaminases and/or glutaminases,
in particular in pro and/or eukaryotes.